These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25323305)

  • 41. Chronic hepatitis B: preventing, detecting, and managing viral resistance.
    Keeffe EB; Dieterich DT; Pawlotsky JM; Benhamou Y
    Clin Gastroenterol Hepatol; 2008 Mar; 6(3):268-74. PubMed ID: 18328434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
    Sun J; Xie Q; Tan D; Ning Q; Niu J; Bai X; Fan R; Chen S; Cheng J; Yu Y; Wang H; Xu M; Shi G; Wan M; Chen X; Tang H; Sheng J; Dou X; Shi J; Ren H; Wang M; Zhang H; Gao Z; Chen C; Ma H; Jia J; Hou J
    Hepatology; 2014 Apr; 59(4):1283-92. PubMed ID: 24382690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O
    Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
    Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
    Hongthanakorn C; Chotiyaputta W; Oberhelman K; Fontana RJ; Marrero JA; Licari T; Lok AS
    Hepatology; 2011 Jun; 53(6):1854-63. PubMed ID: 21618260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.
    De Francesco MA; Gargiulo F; Spinetti A; Zaltron S; Giagulli C; Caccuri F; Castelli F; Caruso A
    New Microbiol; 2015 Jan; 38(1):29-37. PubMed ID: 25742145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The natural course of chronic hepatitis B virus infection and its management.
    Hadziyannis SJ; Vassilopoulos D; Hadziyannis E
    Adv Pharmacol; 2013; 67():247-91. PubMed ID: 23886003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
    Singal AK; Fontana RJ
    Aliment Pharmacol Ther; 2012 Mar; 35(6):674-89. PubMed ID: 22257108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
    Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
    Durantel D; Zoulim F
    J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of chronic hepatitis B].
    Asselah T; Lada O; Marcellin P
    Rev Prat; 2011 Jan; 61(1):45-51. PubMed ID: 21452542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapy with nucleos(t)ide analogues: current role in dialysis patients.
    Fabrizi F; Messa P; Dixit V; Martin P
    Int J Artif Organs; 2010 Jun; 33(6):329-38. PubMed ID: 20669138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential.
    Enomoto M; Tamori A; Nishiguchi S; Kawada N
    J Gastroenterol; 2013 Sep; 48(9):999-1005. PubMed ID: 23338486
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current view on hepatitis B diagnosis and therapy.
    Husa P
    Vnitr Lek; 2019; 65(9):546-551. PubMed ID: 31635465
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiviral Natural Products Against Chronic Hepatitis B: Recent Developments.
    Parvez MK; Arbab AH; Al-Dosari MS; Al-Rehaily AJ
    Curr Pharm Des; 2016; 22(3):286-93. PubMed ID: 26561057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis B therapy.
    Kwon H; Lok AS
    Nat Rev Gastroenterol Hepatol; 2011 May; 8(5):275-84. PubMed ID: 21423260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New treatments to reach functional cure: Virological approaches.
    Durantel D
    Best Pract Res Clin Gastroenterol; 2017 Jun; 31(3):329-336. PubMed ID: 28774415
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [An expert consensus for the adjustment of treatment strategies in patients with chronic hepatitis B treated with non-first-line nucleos(t)ide analogues].
    ;
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):343-346. PubMed ID: 31177657
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Chronic hepatitis B treatment].
    Morović M; Hrstić I
    Acta Med Croatica; 2013 Oct; 67(4):319-23. PubMed ID: 24984331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.